Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIAL FOR TQB3015 "ATR KINASE INHIBITOR" TABLET2023.11.28
-
VOLUNTARY ANNOUNCEMENT - DISPOSAL OF EQUITY INTERESTS IN THREE SUBSIDIARIES2023.11.08
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 20232023.11.01
-
VOLUNTARY ANNOUNCEMENT - SINO BIOPHARMACEUTICAL MSCI ESG RATING UPGRADED TO "A"2023.11.01
-
VOLUNTARY ANNOUNCEMENT - TQG3902 "ANGIOTENSIN II" INJECTION APPROVED FOR CLINICAL TRIAL2023.11.01
-
VOLUNTARY ANNOUNCEMENT - PROGRESS ON THE "SHARE PURCHASE PLAN FOR AN AGGREGATE AMOUNT OF NOT EXCEEDING HK$1 BILLION2023.10.30
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.26
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.10.25